$39.25
-1.50[-3.68%]
At close: May 31
$39.25
0[0.00%]
After Hours: 5:04PM EDT
Apellis Pharmaceuticals: Insider buying and selling updated today.
May 09, 2024 | Pascal Deschatelets | CHIEF SCIENTIFIC OFFICER | 0 | $23.33 | -$3.00M | SELL-OPTIONS | 0.00% | 1.115983M | May 08 | View |
Apr 09, 2024 | Pascal Deschatelets | CHIEF SCIENTIFIC OFFICER | 0 | $28.97 | -$3.48M | SELL-OPTIONS | 0.00% | 1.115983M | Apr 08 | View |
Apr 02, 2024 | Timothy Sullivan | CHIEF FINANCIAL OFFICER | 0 | $34.34 | -$194.52K | SELL-OPTIONS | 0.00% | 149.57K | Apr 01 | View |
Mar 20, 2024 | Sinclair A. Dunlop | — | -18.681K | $57.18 | -$1.07M | SELL | -8.32% | 205.853K | Mar 19 | View |
Mar 19, 2024 | Mark DeLong | CHIEF BUSINESS & STRAT OFFICER | -9.913K | $56.90 | -$564.05K | SELL | -15.34% | 54.693K | Mar 18 | View |
Mar 18, 2024 | James Chopas | VP/CHIEF ACCOUNTING OFFICER | -184 | $56.46 | -$10.39K | SELL | -0.47% | 38.883K | Mar 15 | View |
Mar 14, 2024 | Nur Nicholson | CHIEF TECHNICAL OFFICER | -11.22K | $57.56 | -$645.84K | SELL | -16.62% | 56.287K | Mar 13 | View |
Mar 11, 2024 | Pascal Deschatelets | CHIEF SCIENTIFIC OFFICER | 0 | $32.93 | -$4.04M | SELL-OPTIONS | 0.00% | 1.115983M | Mar 08 | View |
Mar 05, 2024 | Cedric Francois | CHIEF EXECUTIVE OFFICER | 0 | $34.16 | -$14.98M | SELL-OPTIONS | 0.00% | 548.073K | Mar 01 | View |
Mar 05, 2024 | Timothy Sullivan | CHIEF FINANCIAL OFFICER | 0 | $36.63 | -$319.16K | SELL-OPTIONS | 0.00% | 149.57K | Mar 01 | View |
Feb 13, 2024 | David Watson | GENERAL COUNSEL | -781 | $67.77 | -$52.93K | SELL | -0.70% | 110.057K | Feb 12 | View |
Feb 13, 2024 | Adam Townsend | CHIEF COMMERCIAL OFFICER | -1.148K | $67.77 | -$77.80K | SELL | -1.23% | 92.453K | Feb 12 | View |
Feb 13, 2024 | Timothy Sullivan | CHIEF FINANCIAL OFFICER | -1.431K | $67.77 | -$96.97K | SELL | -0.95% | 149.57K | Feb 12 | View |
Feb 13, 2024 | Cedric Francois | CHIEF EXECUTIVE OFFICER | -3.962K | $67.77 | -$268.49K | SELL | -0.72% | 548.073K | Feb 12 | View |
Feb 13, 2024 | Pascal Deschatelets | CHIEF SCIENTIFIC OFFICER | -1.148K | $67.77 | -$77.80K | SELL | -0.10% | 1.115983M | Feb 12 | View |
Feb 13, 2024 | Mark DeLong | CHIEF BUSINESS & STRAT OFFICER | -597 | $67.77 | -$40.46K | SELL | -0.92% | 64.606K | Feb 12 | View |
Jan 31, 2024 | David Watson | GENERAL COUNSEL | -906 | $64.14 | -$58.11K | SELL | -0.81% | 110.838K | Jan 29 | View |
Jan 31, 2024 | Adam Townsend | CHIEF COMMERCIAL OFFICER | -906 | $64.14 | -$58.11K | SELL | -0.96% | 93.601K | Jan 29 | View |
Jan 31, 2024 | Timothy Sullivan | CHIEF FINANCIAL OFFICER | -906 | $64.14 | -$58.11K | SELL | -0.60% | 151.001K | Jan 29 | View |
Jan 31, 2024 | Nur Nicholson | CHIEF TECHNICAL OFFICER | -835 | $64.14 | -$53.56K | SELL | -1.22% | 67.507K | Jan 29 | View |
Jan 31, 2024 | Karen Lewis | CHIEF PEOPLE OFFICER | -1.25K | $65.12 | -$81.40K | SELL | -2.62% | 46.387K | Jan 29 - Jan 30 | View |
Jan 31, 2024 | Cedric Francois | CHIEF EXECUTIVE OFFICER | -2.843K | $64.14 | -$182.34K | SELL | -0.51% | 552.035K | Jan 29 | View |
Jan 31, 2024 | Jeffrey Eisele | CHIEF DEVELOPMENT OFFICER | -1.25K | $65.22 | -$81.52K | SELL | -2.14% | 57.208K | Jan 29 - Jan 30 | View |
Jan 31, 2024 | Pascal Deschatelets | CHIEF SCIENTIFIC OFFICER | -874 | $64.14 | -$56.06K | SELL | -0.08% | 1.117131M | Jan 29 | View |
Jan 31, 2024 | Mark DeLong | CHIEF BUSINESS & STRAT OFFICER | -367 | $64.14 | -$23.54K | SELL | -0.56% | 65.203K | Jan 29 | View |
Jan 24, 2024 | Karen Lewis | CHIEF PEOPLE OFFICER | -4.286K | $63.69 | -$272.98K | SELL | -8.25% | 47.637K | Jan 23 | View |
Jan 24, 2024 | Jeffrey Eisele | CHIEF DEVELOPMENT OFFICER | -7.378K | $63.69 | -$469.90K | SELL | -11.21% | 58.458K | Jan 23 | View |
Jan 23, 2024 | Cedric Francois | CHIEF EXECUTIVE OFFICER | -13.431K | $65.00 | -$872.96K | SELL | -2.36% | 554.878K | Jan 22 | View |
Jan 23, 2024 | David Watson | GENERAL COUNSEL | -4.184K | $65.00 | -$271.94K | SELL | -3.61% | 111.744K | Jan 22 | View |
Jan 23, 2024 | Adam Townsend | CHIEF COMMERCIAL OFFICER | -3.413K | $65.00 | -$221.83K | SELL | -3.49% | 94.507K | Jan 22 | View |
Browse insider trades on all stocks.